lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Benefit of Intensive Atorvastatin Therapy in Sleep Apnea Syndrome with Cardiovascular Disease

23 Pages Posted: 31 Jul 2019

See all articles by Xu Cai

Xu Cai

Ningbo University - Medical School

Jianfeng Huang

Chinese Academy of Sciences (CAS) - Chongqing Renji Hospital

Jingying Su

Shanghai Jiao Tong University (SJTU) - Department of Cardiology

Dadong Zhang

Shanghai Jiao Tong University (SJTU)

Jiangping He

Nujiang People’s Hospital

Yifeng Mai

Ningbo University - Medical School

More...

Abstract

Background: In addition to its hypolipidemic effect, atorvastatin therapy has multiple beneficial effects in patients with cardiovascular disorders. We evaluated the effect of intensive atorvastatin therapy on sleep apnea syndrome (SAS).

Methods: Eighteen patients with apnea-hypopnea index (AHI) ≥5, as assessed by portable monitor, received oral atorvastatin 10 mg/d in the first week and 20 mg/d in the second and third weeks as the preliminary group. Sixteen patients with AHI≥15, as assessed by laboratory polysomnography, received 20 mg/d for two months followed by 40 mg/d for the next two months as the intensive group. If AHI did not reduce by half or to < 15, patients received 60 mg/d from the 5th month onwards.

Results: In the preliminary group, after short-term moderate-dose therapy, AHI was significantly decreased (21.7±13.6 vs. 13.6±12.9, P=0.015), along with a significant increase in average arterial oxyhemoglobin saturation (SaO2) (93.1±2.0 % vs. 93.8±1.2 %, P=0.039). In the intensive group, after mid-term titrated intensive therapy, there was a significantly greater reduction in AHI (36.6±19.8 vs. 11.5±11.5, P=0.0004) with increase in average SaO2 (93.6±2.1% vs. 94.0±1.2%, P=0.017) and minimum SaO2 (71.3±9.5 % vs. 84.3±7.7%, P<0.0001). During follow-up of intensive therapy group, 8 patients (50%) showed a decrease in AHI to < 5 events/h. The degree of AHI reduction and SaO2 amelioration in the intensive group was greater than that in the preliminary group (P<0.01).

Conclusions: Atorvastatin therapy may help reduce AHI and ameliorate hypoxia in patients with SAS. Mid-term intensive dose atorvastatin therapy may be better than short-term moderate dose in this respect.

Funding Statement: Financial support was granted by a Natural Science Fund (09ZR1427500) of the Science and Technology Commission of Shanghai Municipality and a Project for Public Technology Study and Social Development (2010C33SA390002) of Zhejiang Province.

Declaration of Interests: No conflict of interest exists for any of the authors.

Ethics Approval Statement: Our study was approved by Local Ethical Committee in April 1st 2010 (No 201003, Ethical Committee, Yueqing Hospital, Wenzhou Medical University).

Keywords: sleep apnea syndrome; atorvastatin intensive therapy

Suggested Citation

Cai, Xu and Huang, Jianfeng and Su, Jingying and Zhang, Dadong and He, Jiangping and Mai, Yifeng, Benefit of Intensive Atorvastatin Therapy in Sleep Apnea Syndrome with Cardiovascular Disease (07/16/2019 23:27:06). Available at SSRN: https://ssrn.com/abstract=3421601 or http://dx.doi.org/10.2139/ssrn.3421601

Xu Cai (Contact Author)

Ningbo University - Medical School

818 Fenghua Road
Ningbo, 315211
China

Jianfeng Huang

Chinese Academy of Sciences (CAS) - Chongqing Renji Hospital

China

Jingying Su

Shanghai Jiao Tong University (SJTU) - Department of Cardiology ( email )

Ruijin Road 2
Shanghai, 200025
China

Dadong Zhang

Shanghai Jiao Tong University (SJTU)

China

Jiangping He

Nujiang People’s Hospital

Nujiang
China

Yifeng Mai

Ningbo University - Medical School

818 Fenghua Road
Ningbo, 315211
China